277. Lymphangiomatosis
[
6 clinical trials,
2 drugs（DrugBank:
2 drugs),
1 target gene / 43 target pathways ]
Searched query = "Lymphangiomatosis", "Generalized lymphatic anomaly", "Gorham disease", "Gorham Stout disease", "Diffuse lymphangiomatosis", "Mass osteolysis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs031180290 | 16/11/2017 | 7 October 2019 | A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies | A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies - Sirolimus for intractable vascular anomalies | Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lympha Vascular disorders | Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. | Michio Ozeki | Recruiting | Not applicable | Not applicable | Both | 50 | Phase 3 | none | |
| 2 | JPRN-UMIN000030522 | 2017/11/14 | 2 April 2019 | A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies | Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformations | Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. | Gifu University | Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not selected | Japan | ||
| 3 | JPRN-UMIN000029843 | 2017/11/06 | 2 April 2019 | Sirolimus for the treatment of refractory lymphangiomatosis/ Gorham Stout disease | Refractory lymphangiomatosis, Gorham-Stout disease | Oral sirolimus | Kyushu University Hospital | Recruiting | 8years-old | 30years-old | Male and Female | 2 | Not selected | Japan | ||
| 4 | JPRN-UMIN000016580 | 2015/02/01 | 2 April 2019 | Sirolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies | Sirolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies - Sirolimus for vascular anomalies | Lymphangiomatosis, Gorham-Stout disease and vascular anomalies | Oral sirolimus | Gifu university | Not Recruiting | Not applicable | 30years-old | Male and Female | 30 | Phase 1,2 | Japan | |
| 5 | JPRN-UMIN000014888 | 2014/06/01 | 2 April 2019 | Everolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies | Lymphangiomatosis, Gorham-Stout disease and vascular anomalies | Oral everolimus | Gifu university | Not Recruiting | Not applicable | 30years-old | Male and Female | 30 | Phase 1 | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00975819 | October 2009 | 19 February 2015 | Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies | Kaposiform Hemangioendotheliomas;Tufted Angioma;Capillary Venous Lymphatic Malformation;Venous Lymphatic Malformation;Microcystic Lymphatic Malformation;Mucocutaneous Lymphangiomatosis and Thrombocytopenia;Capillary Lymphatic Arterial Venous Malformations;PTEN Overgrowth Syndrome With Vascular Anomaly;Lymphangiectasia Syndromes | Drug: sirolimus | Children's Hospital Medical Center, Cincinnati | Not recruiting | N/A | 31 Years | Both | 60 | Phase 2 | United States |